Micromet, Inc.
http://www.micromet.de
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Micromet, Inc.
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
Pharma On The Hunt For Oncology Partners Across Modalities
The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.
Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva
Mabwell’s denosumab biosimilar MW032, which awaits approval in China, achieved similar efficacy and safety profiles as the originator Xgeva in oncology patients.
CRISPR Therapeutics And Vertex’s CRISPR Breakthrough: How And Why They Got There First
Leaders from the companies explain how they navigated to success with the world’s first CRISPR-based medicine – and avoided the pitfalls that claimed other programs.
Company Information
- Other Names / Subsidiaries
-
- CancerVax Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice